Rocket Pharmaceuticals

RCKT

Market cap $393M

3.63 USD

+0.27

8.04%

At close Updated Dec 10, 4:00 PM EST

Pre-market

After hours

3.61

-0.02

0.55%

1 day

8.04%

5 days

9.34%

1 month

15.24%

3 months

14.15%

6 months

14.87%

Year to date

-71.46%

1 year

-73.13%

5 years

-93.88%

10 years

-91.9%

About: Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.

Employees: 299

Healthcare Biotechnology